{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:26:36Z","timestamp":1789615596848,"version":"build-2803163510"},"reference-count":72,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Boehringer Ingelheim Pharma GmbH&Co. KG, Biberach an der Riss, Germany"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>\n                    DNA damage is an established initiating event in the mutagenicity and carcinogenicity of genotoxic chemicals. Accordingly, assessment of this endpoint is critical for chemicals which are being developed for use in humans. To assess the ability of the Chicken Egg Genotoxicity Assay (CEGA) to detect genotoxic pharmaceuticals, a set of 23 compounds with different pharmacological and reported genotoxic effects was tested for the potential to produce nuclear DNA adducts and strand breaks in the embryo-fetal livers using the\n                    <jats:sup>32<\/jats:sup>\n                    P-nucleotide postlabeling (NPL) and comet assays, respectively. Due to high toxicity, two aneugens, colchicine and vinblastine, and an autophagy inhibitor, hydroxychloroquine, could not be evaluated. Out of the 20 remaining pharmaceuticals, 10 including estrogen modulators, diethylstilbestrol and tamoxifen, antineoplastics cyclophosphamide, etoposide, and mitomycin C, antifungal griseofulvin, local anesthetics lidocaine and prilocaine, and antihistamines diphenhydramine and doxylamine, yielded clear positive outcomes in at least one of the assays. The antihypertensive vasodilator hydralazine and antineoplastics streptozotocin and teniposide, produced only DNA strand breaks, which were not dose-dependent, and thus, the results with these 3 pharmaceuticals were considered equivocal. No DNA damage was detected for 7 compounds, including the purine antagonist 6-thioguanine, antipyretic analgesics acetaminophen and phenacetin, antibiotic ciprofloxacin, antilipidemic clofibrate, anti-inflammatory ibuprofen, and sedative phenobarbital. However, low solubility of these compounds limited dosages tested in CEGA. Overall, results in CEGA were largely in concordance with the outcomes in other systems in vitro and in vivo, indicating that CEGA provides reliable detection of DNA damaging activity of genotoxic compounds. Further evaluations with a broader set of compounds would support this conclusion.\n                  <\/jats:p>","DOI":"10.1177\/10915818221093583","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T03:53:38Z","timestamp":1654314818000},"page":"297-311","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of Pharmaceuticals for DNA Damage in the Chicken Egg Genotoxicity Assay (CEGA)"],"prefix":"10.1177","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8207-5035","authenticated-orcid":false,"given":"Tetyana","family":"Kobets","sequence":"first","affiliation":[{"name":"Department of Pathology, Immunology and Microbiology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Dong","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Immunology and Microbiology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Vock","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH&Co. KG, Biberach an der Riss, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Deschl","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH&Co. KG, Biberach an der Riss, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Pathology, Immunology and Microbiology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"bibr1-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/0027-5107(95)00221-9"},{"key":"bibr2-10915818221093583","volume-title":"S1A Guideline on the need for carcinogenicity studies of pharmaceuticals","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)","year":"1995"},{"key":"bibr3-10915818221093583","first-page":"1251","volume-title":"Hayes principles and methods of toxicology","author":"Williams G","year":"2014","edition":"6"},{"key":"bibr4-10915818221093583","volume-title":"Guidance for industry. S2(R1) Genotoxicity testing and data interpretation for pharmaceuticals intended for human use. Safety Implementation Working Group","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)","year":"2012"},{"key":"bibr5-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2010.12.015"},{"key":"bibr6-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2006.10.003"},{"key":"bibr7-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1039\/c8tx00250a"},{"key":"bibr8-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1080\/10408440591007278"},{"key":"bibr9-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1080\/10408444.2017.1423462"},{"key":"bibr10-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801238-3.64088-6"},{"key":"bibr11-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(75)97171-2"},{"key":"bibr12-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-014-1415-3"},{"key":"bibr13-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(85)90144-3"},{"key":"bibr14-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(78)80049-4"},{"key":"bibr15-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1110(89)90039-0"},{"key":"bibr16-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(88)90094-4"},{"key":"bibr17-10915818221093583","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2020.611913"},{"key":"bibr18-10915818221093583","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.626805"},{"key":"bibr19-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/j.etp.2017.04.011"},{"key":"bibr20-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2018.03.015"},{"key":"bibr21-10915818221093583","first-page":"82","volume":"166","author":"Kobets T","year":"2018","journal-title":"Toxicol Sci"},{"key":"bibr22-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2019.06.004"},{"key":"bibr23-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-011-0653-x"},{"key":"bibr24-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfu123"},{"key":"bibr25-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-739-6_10"},{"key":"bibr26-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1002\/0471140856.tx0312s65"},{"key":"bibr27-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfv322"},{"key":"bibr28-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2019.05.010"},{"key":"bibr29-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/7.9.1543"},{"key":"bibr30-10915818221093583","first-page":"5656","volume":"45","author":"Gupta RC","year":"1985","journal-title":"Cancer Res"},{"key":"bibr31-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1787\/9789264264885-en"},{"key":"bibr32-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.019950"},{"key":"bibr33-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1007\/s002040050068"},{"key":"bibr34-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/15.10.2087"},{"key":"bibr35-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(93)90146-Z"},{"key":"bibr36-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90143-7"},{"key":"bibr37-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/gei038"},{"key":"bibr38-10915818221093583","first-page":"1265","volume-title":"Principles and methods of toxicology","author":"Williams G","year":"2007","edition":"1"},{"key":"bibr39-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.12.7377"},{"key":"bibr40-10915818221093583","volume-title":"IARC monographs on the evaluation of carcinogenic risks to humans. Some thyrotropic agents. Volume 79IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","author":"International Agency for Research on Cancer (IARC)","year":"2001"},{"key":"bibr41-10915818221093583","volume-title":"NTP technical report on the toxicology and carcinogenesis studies of diphenhydramine hydrochloride (CAS no. 147-24-0) in F344\/N rats and B6c3F1 mice (feed studies)","author":"National Toxicology Program (NTP)","year":"1989"},{"key":"bibr42-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-011-0659-4"},{"key":"bibr43-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/S1383-5742(98)00016-7"},{"key":"bibr44-10915818221093583","volume-title":"Overall evaluations of carcinogenicity: An updating of IARC monographs volumes 1 to 42. Supplement 7IARC working group on the evaluation of carcinogenic risks to humans","author":"International Agency for Research on Cancer (IARC)","year":"1987"},{"key":"bibr45-10915818221093583","volume-title":"IARC monographs on the evaluation of carcinogenic risks to humans. Review of human carcinogens. Pharmaceuticals. Volume 100A. IARC working group on the evaluation of carcinogenic risks to humans","author":"International Agency for Research on Cancer (IARC)","year":"2012"},{"key":"bibr46-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1126\/science.7423193"},{"key":"bibr47-10915818221093583","first-page":"601","volume":"86","author":"Rougraff PM","year":"1987","journal-title":"Comp Biochem Physiol"},{"key":"bibr48-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1997.8311"},{"key":"bibr49-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1097\/01.cej.0000243854.12728.b8"},{"key":"bibr50-10915818221093583","volume-title":"IARC monographs on the evaluation of carcinogenic risks to humans. Some chemicals that cause tumors of the kidney or urinary bladder in rodents and some other substances. Volume 73IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","author":"International Agency for Research on Cancer (IARC)","year":"1999"},{"key":"bibr51-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1097\/00008469-199708000-00007"},{"key":"bibr52-10915818221093583","first-page":"454","volume":"33","author":"Yamamoto RS","year":"1973","journal-title":"Cancer Res"},{"key":"bibr53-10915818221093583","first-page":"3246","volume":"49","author":"Cattley RC","year":"1989","journal-title":"Cancer Res"},{"key":"bibr54-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(96)00067-8"},{"key":"bibr55-10915818221093583","first-page":"3665","volume":"44","author":"Christie NT","year":"1984","journal-title":"Cancer Res"},{"key":"bibr56-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1021\/cb100214b"},{"key":"bibr57-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldl020"},{"key":"bibr58-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1007\/BF00717792"},{"key":"bibr59-10915818221093583","first-page":"2327","volume":"9","author":"Yan T","year":"2003","journal-title":"Clin Cancer Res"},{"key":"bibr60-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/0027-5107(74)90068-2"},{"key":"bibr61-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.80"},{"key":"bibr62-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-004-0580-1"},{"key":"bibr63-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/19.5.861"},{"key":"bibr64-10915818221093583","first-page":"5518","volume":"54","author":"Phillips DH","year":"1994","journal-title":"Cancer Res"},{"key":"bibr65-10915818221093583","volume-title":"IARC monographs on the evaluation of carcinogenic risks to humans. Some antiviral and antineoplastic drugs, and other pharmaceutical agents","volume":"76","author":"International Agency for Research on Cancer (IARC)","year":"2000"},{"key":"bibr66-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2005.08.011"},{"key":"bibr67-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2280(1998)31:4<345::AID-EM7>3.0.CO;2-H"},{"key":"bibr68-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1016\/S1383-5718(01)00275-3"},{"key":"bibr69-10915818221093583","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.2.213"},{"key":"bibr70-10915818221093583","volume-title":"IARC monographs on the evaluation of carcinogenic risks to humans. Some pharmaceutical drugs. Volume 66IARC working group on the evaluation of carcinogenic risks to humans","author":"International Agency for Research on Cancer (IARC)","year":"1996"},{"key":"bibr71-10915818221093583","first-page":"1360","volume":"52","author":"Han XL","year":"1992","journal-title":"Cancer Res"},{"key":"bibr72-10915818221093583","first-page":"1033","volume":"7","author":"Warren AJ","year":"2001","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10915818221093583","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10915818221093583","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10915818221093583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:24:17Z","timestamp":1777458257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10915818221093583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1177\/10915818221093583"],"URL":"https:\/\/doi.org\/10.1177\/10915818221093583","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,4]]}}}